NYSEAMERICAN:MAIA MAIA Biotechnology (MAIA) Stock Price, News & Analysis $1.74 -0.04 (-2.25%) As of 10:07 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestBuy This Stock About MAIA Biotechnology Stock (NYSEAMERICAN:MAIA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get MAIA Biotechnology alerts:Sign Up Key Stats Today's Range$1.71▼$1.7950-Day Range$1.44▼$1.9852-Week Range$1.40▼$5.99Volume32,810 shsAverage Volume230,699 shsMarket Capitalization$45.52 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewMAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer. It is also developing second generation telomere targeting agents. The company was incorporated in 2018 and is headquartered in Chicago, Illinois.Read More… MAIA Biotechnology Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks6th Percentile Overall ScoreMAIA MarketRank™: MAIA Biotechnology scored higher than 6% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for MAIA Biotechnology. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for MAIA Biotechnology are expected to decrease in the coming year, from ($1.30) to ($1.35) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of MAIA Biotechnology is -1.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of MAIA Biotechnology is -1.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMAIA Biotechnology has a P/B Ratio of 58.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about MAIA Biotechnology's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.42% of the float of MAIA Biotechnology has been sold short.Short Interest Ratio / Days to CoverMAIA Biotechnology has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in MAIA Biotechnology has recently increased by 4.05%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMAIA Biotechnology does not currently pay a dividend.Dividend GrowthMAIA Biotechnology does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted3.42% of the float of MAIA Biotechnology has been sold short.Short Interest Ratio / Days to CoverMAIA Biotechnology has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in MAIA Biotechnology has recently increased by 4.05%, indicating that investor sentiment is decreasing. News and Social Media0.6 / 5News SentimentN/A Search Interest3 people have searched for MAIA on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added MAIA Biotechnology to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, MAIA Biotechnology insiders have not sold or bought any company stock.Percentage Held by Insiders36.98% of the stock of MAIA Biotechnology is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 5.65% of the stock of MAIA Biotechnology is held by institutions.Read more about MAIA Biotechnology's insider trading history. Receive MAIA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MAIA Biotechnology and its competitors with MarketBeat's FREE daily newsletter. Email Address MAIA Stock News HeadlinesMAIA Biotechnology CEO Details Anticipated Clinical Milestones for Novel Cancer Immunotherapy in 2025 Letter to ShareholdersApril 1, 2025 | businesswire.comIs MAIA Biotechnology, Inc. (MAIA)he Cheapest Stock Insiders Are Buying In March?March 28, 2025 | insidermonkey.comTrump purposefully forcing markets to crash…Whether you agree with the plan or not doesn’t matter. It’s happening. The only question is – are you ready for it?April 22, 2025 | Porter & Company (Ad)MAIA Biotechnology Announces Poster Presentation at ESMO's European Lung Cancer Congress 2025March 25, 2025 | businesswire.comMAIA Biotechnology Gets USAN Approval For "Ateganosine" As Name For Telomere-Targeting DrugMarch 21, 2025 | nasdaq.comMAIA Biotechnology publishes preclinical data for telomere-targeting THIO dimerMarch 21, 2025 | msn.comMAIA Biotechnology Announces Publication of Peer-Reviewed Study Featuring Potency and Potential of Novel THIO ProdrugMarch 20, 2025 | businesswire.comMAIA Biotechnology Receives USAN Council Approval for "Ateganosine" as Nonproprietary Name for Anticancer Agent THIOMarch 19, 2025 | uk.finance.yahoo.comSee More Headlines MAIA Stock Analysis - Frequently Asked Questions How have MAIA shares performed this year? MAIA Biotechnology's stock was trading at $2.09 at the start of the year. Since then, MAIA stock has decreased by 16.7% and is now trading at $1.74. View the best growth stocks for 2025 here. How were MAIA Biotechnology's earnings last quarter? MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) issued its quarterly earnings results on Tuesday, November, 12th. The company reported ($0.11) EPS for the quarter, beating analysts' consensus estimates of ($0.32) by $0.21. How do I buy shares of MAIA Biotechnology? Shares of MAIA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of MAIA Biotechnology own? Based on aggregate information from My MarketBeat watchlists, some other companies that MAIA Biotechnology investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Jabil (JBL), Adobe (ADBE) and AppLovin (APP). Company Calendar Last Earnings11/12/2024Today4/22/2025Next Earnings (Estimated)5/13/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNYSEAMERICAN:MAIA CIK1878313 Webwww.MAIABiotech.com Phone312-416-8592FaxN/AEmployees9Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.38) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-19,770,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-14,708.83% Return on Assets-221.26% Debt Debt-to-Equity RatioN/A Current Ratio2.56 Quick Ratio2.56 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.03 per share Price / Book58.00Miscellaneous Outstanding Shares26,160,000Free Float16,485,000Market Cap$45.52 million OptionableNot Optionable Beta0.20 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free Report This page (NYSEAMERICAN:MAIA) was last updated on 4/22/2025 by MarketBeat.com Staff From Our PartnersWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredTrump’s tariffs just split the AI market in twoTrump’s tariff just split the AI market – among others – in two. One group of AI companies—the ones relying...Traders Agency | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrade War Just Turned 3 Unknown Stocks Into Rocket FuelThe Real Catalyst Behind America’s Next Bull Run One overlooked sector is being completely repriced — and s...Insiders Exposed | Sponsored‘Wheels Are Falling Off’ the U.S. Stock MarketThe last time the U.S. economy looked like this, stocks didn't move for 16 years... And many investors lost...Stansberry Research | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MAIA Biotechnology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MAIA Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.